Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended March 31, 2024 and 2023 is as follows:

	Three Months Ended March 31, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	1,287	$	13,394	$	-			$	14,681
Cost of revenues (excluding amortization of acquired intangible assets)		-			177		1,463		-				1,640
Direct expenses		5,465			416		4,414		9,576				19,871
Segment contribution	$	(5,465	)	$	694	$	7,517		(9,576	)			(6,830	)
Indirect expenses									546		(a)		546
Loss from operations												$	(7,376	)
(a) Components of other
Amortization									546
Total other								$	546

	Three Months Ended March 31, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	1,357	$	2,578		$	-			$	3,935
Cost of revenues (excluding amortization of acquired intangible assets)		-			472		1,531			-				2,003
Direct expenses		40,162			344		3,009			11,155				54,670
Segment contribution		(40,162	)		541		(1,962	)		(11,155	)			(52,738	)
Indirect expenses										11,132		(b)		11,132
Loss from operations													$	(63,870	)
(b) Components of other
Change in fair value of contingent consideration liability										(18,932	)
Change in fair value of contingent stock consideration										(110	)
Goodwill impairment										29,633
Amortization										541
Total other									$	11,132